FDA Approves Imlunestrant and Abemaciclib Combination

Company Eli Lilly Event Type FDA Approval Modality Oral SERD (Imlunestrant) Plus CDK4/6 Inhibitor (Abemaciclib) Target Estrogen Receptor / CDK4 and CDK6 Disease Area ER-Positive, HER2-Negative, ESR1-Mutated Advanced or Metastatic Breast Cancer Summary FDA approved imlunestrant plus abemaciclib for adults with ER-positive, HER2-negative, ESR1-mutated advanced…